Purchase by Sanjay Shukla of 15000 shares of ATyr Pharma
About 67% of ATyr Pharma's investor base is looking to short. The analysis of current outlook of investing in ATyr Pharma suggests that many traders are alarmed regarding ATyr Pharma's prospects. The current market sentiment, together with ATyr Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use ATyr Pharma stock news signals to limit their universe of possible portfolio assets.
ATyr |
Filed transaction by Atyr Pharma Inc director. General open market or private purchase of non-derivative or derivative security
Read at macroaxis.com
ATyr Pharma Fundamental Analysis
We analyze ATyr Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ATyr Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ATyr Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
ATyr Pharma is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
ATyr Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ATyr Pharma stock to make a market-neutral strategy. Peer analysis of ATyr Pharma could also be used in its relative valuation, which is a method of valuing ATyr Pharma by comparing valuation metrics with similar companies.
Peers
ATyr Pharma Related Equities
| INZY | Inozyme Pharma | 6.41 | ||||
| ABOS | Acumen Pharmaceuticals | 2.78 | ||||
| DAWN | Day One | 2.65 | ||||
| AMLX | Amylyx Pharmaceuticals | 2.27 | ||||
| MREO | Mereo BioPharma | 1.82 | ||||
| TERN | Terns Pharmaceuticals | 3.14 | ||||
| XFOR | X4 Pharmaceuticals | 4.69 | ||||
| HOOK | Hookipa Pharma | 5.61 | ||||
| PDSB | PDS Biotechnology | 5.71 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in ATyr Stock
If you are still planning to invest in ATyr Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ATyr Pharma's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |